The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Open accessAbstract
As the incidence of Gram-negative bacterial infections for which few effective treatments remain increases, so does the contribution of drug-hydrolyzing β-lactamase enzymes to this serious clinical problem. This review highlights recent advances in β-lactamase inhibitors and focuses on agents with novel mechanisms of action against a wide range of enzymes. To this end, we review the β-lactamase inhibitors currently in clinical trials, select agents still in preclinical development, and older therapeutic approaches that are being revisited. Particular emphasis is placed on the activity of compounds at the forefront of the developmental pipeline, including the diazabicyclooctane inhibitors (avibactam and MK-7655) and the boronate RPX7009. With its novel reversible mechanism, avibactam stands to be the first new β-lactamase inhibitor brought into clinical use in the past 2 decades. Our discussion includes the importance of selecting the appropriate partner β-lactam and dosing regimens for these promising agents. This “renaissance” of β-lactamase inhibitors offers new hope in a world plagued by multidrug-resistant (MDR) Gram-negative bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367 · cited 1×
“As a class, these OXA -lactamases are not effectively inactivated by the available -lactam-type inhibitors; however, in vitro, concentrations of NaCl 100 mM inactivate most class D enzymes (103, 104).”
BackgroundAgents that increase the permeability of the outer membrane
Vaara, M. (1992) · Microbiological Reviews · doi:10.1128/mr.56.3.395-411.1992 · Cited by 1,879 · cited 1×
“In addition to chelating the zinc ions required for MBL hydrolysis, ion chelation may disrupt bacterial cell membranes and help disperse bacterial biofilms (94, 95).”
BackgroundThree Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Self-citationTackling antibiotic resistance
Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G. A., Kishony, R., Kreiswirth, B. N., Kutter, E., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2693 · Cited by 1,062
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Cited by
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., & Zong, Z. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-18 · Cited by 700
Update on the antibiotic resistance crisis
Rossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.006 · Cited by 695
β-lactam antibiotics: An overview from a medicinal chemistry perspective
Lima, L. M., Silva, B. N. M. D., Barbosa, G., & Barreiro, E. J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112829 · Cited by 642
Next-generation approaches to understand and combat the antibiotic resistome
Crofts, T. S., Gasparrini, A. J., & Dantas, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.28 · Cited by 535
Interplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
Self-citationMechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Therapeutic strategies to combat antibiotic resistance
Brooks, B. D., & Brooks, A. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.027 · Cited by 367
The emerging threat of multidrug-resistant Gram-negative bacteria in urology
Zowawi, H. M., Harris, P. N. A., Roberts, M. J., Tambyah, P. A., Schembri, M. A., Pezzani, M. D., Williamson, D. A., & Paterson, D. L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.199 · Cited by 361
Treating infections caused by carbapenemase-producing Enterobacteriaceae
Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M., & Daikos, G. L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12697 · Cited by 337
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Marshall, S., Hujer, A. M., Rojas, L. J., Papp-Wallace, K. M., Humphries, R. M., Spellberg, B., Hujer, K. M., Marshall, E. K., Rudin, S. D., Perez, F., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02243-16 · Cited by 293
Self-citationEnvelope Structures of Gram-Positive Bacteria
Rajagopal, M., & Walker, S. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2015_5021 · Cited by 292
Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Bollenbach, T. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.05.008 · Cited by 261
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections
Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R. W., Empting, M., & Titz, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01698 · Cited by 258
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Self-citationAntibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics
González-Bello, C. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.027 · Cited by 254
Metadata
- Authors
- Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-04
- Volume
- 58
- Issue
- 4
- Pages
- 1835-1846
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2139911027
- Cited by
- 286
- References
- 99
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.